Can a diabetes drug stop prediabetes in its tracks?
NCT ID NCT05426525
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether empagliflozin, a drug used for type 2 diabetes, can improve blood sugar control in 60 overweight or obese adults with prediabetes. Participants take the drug or a placebo for 13 weeks. The goal is to see if the drug helps the body use sugar better and lowers the risk of developing diabetes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oregon State University
Corvallis, Oregon, 97331, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Daily pill could offer new hope for weight loss in east asian adults
- A new rice could tame blood sugar spikes in prediabetes
- Could everyday supplements turn back the clock on aging?
- Can a single pill tackle both fatty liver and diabetes?
- Does when you eat carbs and protein reshape blood sugar control?
- Could a daily glass of milk help ward off type 2 diabetes?